1. Brazil Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Baumer SA

Baumer SA

22.00
BRL
0.00
(0.00%)
2.66EPS
10.99P/E
254.40MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
11.09
11.87
11.43
11.54
11.2
12.22
15.24
33.26
54.62
16.79
17.34
39.67
43.62
21.46
Basic EPS, GAAP
0.62
1.17
1.46
0.31
0.07
0.28
0.43
1.68
2.07
0.58
0.91
6.45
3.69
2.37
Free Cash Flow per Basic Share
0.55
0.06
0.15
-0.56
0.37
-0.58
0.72
2.12
2.62
-0.3
2.41
6.38
11.2
3.78
Dividend per Share
0.2
0.34
0.32
0.45
0.24
0.22
0.22
0.24
0.99
0.49
- -
1.53
12.46
5.44
Book Value per Share
6.91
7.53
8.79
8.94
9.05
9.61
10.27
11.56
13.04
13.65
14.74
18.19
15.64
17.16
Tangible Book Value per Share
6.71
7.33
8.72
8.88
9
9.47
10.1
11.41
12.89
13.51
14.62
18.06
15.52
17.03
Basic Weighted Avg Shares
10
10
10
10
10
10
10
10
5
10
10
5
5
10
Sales/Revenue/Turnover
109
116
112
113
110
120
149
326
268
165
170
194
214
205
Operating Margin (%)
17.58
14.82
12.77
8.19
3.03
4.51
6.14
55.23
54.57
10.87
12.85
18.94
18.46
16.86
Depreciation Expense
2
2
2
3
3
3
3
3
5
4
5
5
6
6
Net Income, GAAP
13
11
14
3
1
3
4
16
10
6
9
32
18
23
Effective Tax Rate (%)
30.05
32.26
29.39
48.36
81.15
53.58
55.52
22.59
24.55
41
38.82
25.86
25.93
20.98
Profit Margin (%)
12.08
9.89
12.81
2.67
0.62
2.3
2.81
5.04
3.79
3.47
5.26
16.26
8.46
11.02
Working Capital
50
51
65
53
50
56
52
66
96
106
114
137
114
136
LT Debt
8
11
16
22
18
17
15
12
15
19
16
14
19
26
Total Equity
76
82
95
98
101
104
108
121
129
135
146
175
144
161
Return on Invested Capital (%)
16.36
12.36
9.58
2.18
0.34
2.02
2.95
100.12
76.44
6.91
8.38
15.58
16.67
13.67
Return on Capital (%)
16.29
13.44
15.79
3
0.84
2.46
3.44
12.32
7.82
4.61
9.07
22.6
12.33
14.54
Return on Common Equity (%)
9.82
16.24
17.94
3.47
0.77
3.02
4.31
15.38
8.41
4.37
6.44
19.62
10.92
12.95

Capital Structure

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3
2
2
LT Borrowings
19
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
274
254
254

Working Capital

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
202
207
216
Cash, Cash Equivalents & STI
67
69
71
Accounts Receivable, Net
45
45
44
Inventories
68
71
77
Total Current Liabilities
88
87
80
Payables & Accruals
- -
- -
- -
ST Debt
3
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

BRL

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.67%
4.26%
-17.51%
Free Cash Flow
-187.76%
-191.2%
75.48%
Net Income, GAAP
68.07%
37.06%
-42.81%
Sales/Revenue/Turnover
12.13%
-5.76%
9.95%
Total Cash Common Dividend
- -
- -
715.74%

Quarterly Revenue

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
36
46
54
58
194
2025
49
57
55
52
214
2026
48
50
- -
- -
- -

Quarterly Earnings Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.41
0.85
0.64
1.27
6.45
2025
0.49
0.64
0.14
0.83
3.69
2026
0.53
0.86
- -
- -
- -

Quarterly Dividends Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.32
0.89
-0.43
1.53
2025
0.83
1.37
-0.34
4.86
12.46
2026
0.03
0.77
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ruy Salvari Baumer
Full Time Employees
6
Sector
Health technology
Industry
Medical specialties
Address
Avenida Arnolfo Azevedo, 210 Mogi Mirim SP Brazil 01236-030
IPO Date
Jun 6, 1995
Website
baumer.com.br
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Baumer S.A. (BALM3.SA) manufactures and markets medical and hospital equipment, orthopedic implants, biomaterials, and infection control solutions for healthcare providers; it offers bone regeneration products including GenOx grafts, OrthoGen granules and blocks, GenPhos bone substitutes, and membranes such as GenDerm and TechGraft; sterilization equipment encompassing steam sterilizers in Hi Vac II, Hi Speed II, and Nurse II lines, hydrogen peroxide PHB sterilizers, waste treatment autoclaves, and pure steam generators; cleaning solutions like washer-disinfectors in TW and TWD lines, ultrasonic cleaners, and detergents; water treatment systems; operating room equipment including surgical tables A0100 series, multiparametric monitors Q7, M12, and P models, and surgical lights; orthopedic devices comprising conventional and non-conventional prostheses, trauma instruments, spinal and neurosurgery products, and bone cements; as well as maintenance services such as preventive and corrective repairs, calibration, equipment upgrades, and industrial sterilization validation using ethylene oxide and hydrogen peroxide. The company, founded in 1952 and headquartered in Mogi Mirim, São Paulo state, Brazil, with additional facilities in Pacaembu, operates primarily in Brazil and exports to over 36 countries, serving more than 4,000 hospitals through its modern 60,000-square-meter industrial park focused on orthopedics, safe environments, bone regeneration, and equipment segments; it provides technical assistance, imports, exports, and training for hospital, pharmaceutical, dental, and industrial applications. Recent developments include sustained revenue growth to BRL 218.37 million trailing twelve months as of 2025 with net income of BRL 41.05 million, reflecting a 14.38% increase from prior year amid expanded operations in infection prevention and orthopedic solutions post-COVID adaptations, alongside ongoing innovation in national technologies for prosthetics and sterilization to meet regulatory standards and enhance patient outcomes in domestic and international markets.